SBH Diagnostics (SBHD) is an innovative Contract Research Organization and CLIA Lab dedicated to providing accurate and reproducible biomarker analysis services. We are focused on the commercialization of Laboratory Developed Tests (LDTs). In the SBH Diagnostics portfolio under CLIA auspices are the Pico-molar C-Peptide test, the High-specific Glucagon Test and and the EASy-Sjogren's test using the Automatic Simple Western process. SBHD is located in Natick, MA and is associated with SBH Sciences and GlycoZym.
SBH Sciences provides cell-based discovery and preclinical process development services based on its expertise in cell culture, biologic production, and biomarker development. The company's extensive, innovative cell based cytokine and cancer drug profiling assays (using over 180 human cancer cell lines), provide time and cost effective tools for screening drug candidates and optimizing therapeutics leads mainly in Oncology and Inflammation. SBH Sciences has comprehensive preclinical production capabilities for biologics, from DNA to final pure active product. Moreover, the company's immunological expertise provides a rapid path to biomarker discovery, optimization and implementation of new diagnostics tools.
GlycoZym USA Inc. is a world-leader in the discovery and development of biomarkers for cancer and autoimmune diseases. Since the start of laboratory operations in the beginning of 2009, GlycoZym's focus has been on the development of biomarker libraries that are displayed on microarrays (Chips) that can probe the human immune system for signatures of disease or effects of disease treatment. GlycoZym's competitive advantage centers on its proprietary technologies (16 issued US patents) and compound libraries that allow for high throughput screening of immunity to naturally occurring disease modified proteins.
Automated Western Analysis Services
We are excited to introduce a new and innovative CRO protein analysis service in our CLIA registered lab for Pharmaceutical and Biotech Companies using traditional western blots in their research, development, and QC labs.
A major challenge in protein research is obtaining quantitative, reproducible, high content information quickly. SBH Diagnostics offers a new automated process (Simple WesternTM) using a novel capillary electrophoresis (CE) based immunodetection platform for protein separation and characterization. Proteins can be separated by size as in traditional PAGE Western or by their pI as in traditional CE.
The SBH Diagnostics Service offers Simple WesternTM currently used in big pharma for vaccine development, cell lysate analysis (from tissue culture or tumors), identification and quantitation of tumor-associated proteins, focusing on key kinase inhibitor targets in precious clinical patient samples.
Benefits of the new SBH Diagnostic Western Service
The Simple WesternTM Protein Analysis can provide:
SBH Diagnostics is an innovative CLIA certified Contract Research Organization dedicated to providing accurate and reproducible biomarker analysis services.
Cytokine measurement can support many therapeutics discovery programs including cardiovascular, inflammation, immunology, oncology, metabolic syndrome and CNS disorders. The cytokine analysis can be used as an indicator of drug's efficacy (e.g., monoclonal antibodies project), but also as a companion diagnostic to support clinical studies.
We are pleased to offer ELISA and Multiplex analysis of many cytokines including: BMPs, EGF, FGF, G-CSF, GM-CSF, IFN-gamma, IGF, IGF-BPs, IL-1b, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-17, IP-10, Leptin, MCP-1, M-CSF, MIG, MIP-1a, beta-NGF, PDGF, SCF, TNF-alpha, TPO, TRAIL and VEGF.
We are providing custom service that will meet your specific needs. We can test many other cytokines and biomarkers. We work with biological matrices from humans or animals, as well as both small and large therapeutic molecules.
SBH Diagnostics has not received any reviews.
SBH Diagnostics has not received any endorsements.